ClinicalTrials.gg
CompletedNCT05523089Updated Sep 19, 2024Results posted

The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults

A Phase 2 interventional study of Saline placebo and CD388 in Influenza, sponsored by Cidara Therapeutics Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Cidara Therapeutics Inc. (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies in Influenza, Human with a site in United Kingdom — 8 open to participants now, 13 under way, 4 of them phase 3. Influenza, Human · United Kingdom.

Enrollment
96th of 123
59 · median 129
Started
2022
with 6 others
Phase 2
38 of 151
2 open now
Registered
128th of 151
by date

Among the 151 studies in Influenza, Human with a site in United Kingdom, this one is the 96th largest by enrollment of the 123 interventional ones that give a count, is one of 7 that started in 2022, is one of 38 in phase 2, and was the 128th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

8 of the 151 studies in Influenza, Human with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Influenza, Human with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.

Read the detailed description

This is a single-center, randomized, double-blind, placebo-controlled, proof-of-concept study in healthy adult male and female participants 18 to 55 years of age, inclusive. The primary goal of this Phase 2a study is to assess the prophylactic antiviral activity against influenza, safety, tolerability, and pharmacokinetics (PK) of CD388 via a human viral challenge (HVC) model, and to explore the impact of dose levels on efficacy. Each participant will receive a single administration of CD388 or placebo; multiple dose levels of CD388 may be evaluated.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written signed and dated by the participant and the PI/investigator obtained before any assessment is performed.
  2. Adult male or female aged between 18 and 55 years old, inclusive, on the day prior to signing the consent form.
  3. A total body weight ≥50 kilograms (kg) and (BMI) ≥18 kg/meter squared (m\^2) and ≤35kg/m\^2.
  4. In good health with no history, or current evidence, of medical conditions, and no clinically significant test abnormalities that will interfere with participant safety, as defined by medical history, physical examination (including vital signs), (ECG), and routine laboratory tests as determined by the Principal Investigator (PI)/investigator.
  5. Participants will have a documented medical history either prior to entering the study or following medical history review with the study physician at screening.
  6. The following criteria are applicable to female participants participating in the study.

    1. Females of must have a negative pregnancy test prior to enrolment.
    2. Females of non-childbearing potential:

      1. females defined as amenorrhea for ≥12 months with no alternative medical cause. A high follicle-stimulating hormone (FSH) level, within appropriate postmenopausal range, may be used to confirm postmenopausal state in the absence of combined hormonal or hormone replacement therapy. If there is \<12 months of amenorrhea 2 FSH samples are required at least 4 to 6 weeks apart.
      2. Documented status as being surgically sterile (e.g., tubal ligation, hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
  7. The following criteria apply to female and male participants:

    1. Female participants of childbearing potential must use 1 form of highly effective contraception. Hormonal methods must be in place from at least 2 weeks prior to the first study visit. The contraception use must continue until 5 effective half-lives (205 days) after the last dose of medicinal product (IMP). Highly effective contraception is as described below:

      1. Established use of hormonal methods of contraception described below (for a minimum of 30 days prior to the first study visit). When hormonal methods of contraception are used, male partners are required to use a condom with a spermicide:

        • a) combined (estrogen- and progestogen containing) hormonal contraception associated with inhibition of ovulation:

          • (i) oral
          • (ii) intravaginal
          • (iii) transdermal
        • b) progestogen-only hormonal contraception associated with inhibition of ovulation:

          • (i) oral
          • (ii) injectable
          • (iii) implantable
      2. Intrauterine device.
      3. Intrauterine hormone-releasing system.
      4. Bilateral tubal ligation.
      5. Male sterilization (with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate) where the vasectomized male is the sole partner for that woman.
      6. True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant.
    2. Male participants must agree to the contraceptive requirements below at entry to quarantine and continuing until 5 effective half-lives (205 days) after the last dose of IMP.

      1. Use a condom with a spermicide to prevent pregnancy in a female partner or to prevent exposure of any partner (male or female) to the IMP.
      2. Male sterilization with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate (please note that the use of condom with spermicide will still be required to prevent partner exposure). This applies only to males participating in the study.
      3. In addition, for female partners of childbearing potential, that partner must use another form of contraception such as one of the highly effective methods mentioned above for female participants.
      4. True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant.
    3. In addition to the contraceptive requirements above, male participants must agree not to donate sperm following discharge from quarantine until 5 effective half-lives (205 days) after the last dose of IMP.
  8. Sero-suitable for the challenge virus. A participant must be sero-suitable to take part in the study, i.e., he/she must have no or low pre-existing serum levels of antibodies specific to the challenge agent. Serology testing will be carried out by a hemagglutination inhibitory assay to determine serum antibody titers. As an example, a participant is considered sero-suitable if their serology (hemagglutination inhibition [HAI]) titer result is ≤10.

Exclusion criteria

Exclusion Criteria:

  1. History of, or currently active, symptoms or signs suggestive of upper respiratory tract (URT) or lower respiratory tract (LRT) infection within 4 weeks prior to the first study visit.
  2. Any history or evidence of any or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, hematological, hepatic, immunological (including ), metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease that, in the opinion of the PI/investigator may interfere with a participant completing the study and necessary investigations. The following conditions apply:

    1. Participants with a history of resolved depression and/or anxiety 1 or more years ago can be included if the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder Questionnaire (GAD-7) is less than or equal to 4 on admission. Participants with a history of stress-related illness, which is not ongoing or requiring current therapy, with good evidence of preceding stressors may be included at the PI's discretion. As required, participants will be assessed prior to enrolment with a PHQ-9 and GAD-7 questionnaire.
    2. Rhinitis (including hay fever) which is clinically active or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal on an at least weekly basis, within 30 days of admission to quarantine will be excluded. Participants with a history of currently inactive rhinitis (within the last 30 days) or mild rhinitis may be included at the PI's discretion.
    3. Atopic dermatitis/eczema which is clinically severe and/or requiring moderate to large amounts of daily dermal corticosteroids will be excluded. Participants with mild to moderate atopic dermatitis/eczema, taking small amounts of regular dermal corticosteroids may be included at the PI's discretion.
    4. Any concurrent serious illness, including history of , that may interfere with a participant completing the study. Basal cell carcinoma within 5 years of initial diagnosis or with evidence of recurrence is also an exclusion.
    5. Participants reporting physician-diagnosed migraine can be included provided there are no associated neurological symptoms such as hemiplegia or visual loss. Cluster headache/migraine or prophylactic treatment for migraine is an exclusion.
    6. Participants with physician diagnosed mild irritable bowel syndrome not requiring regular treatment can be included at the discretion of the PI.
    7. Participants with a history of asthma where their last symptoms/treatment were in adolescence and over 6 years ago may be included at the discretion of the PI. Any participants with symptoms or treatment in adulthood would be excluded.
  3. Any participants who have smoked ≥10 pack years at any time (10 pack years is equivalent to 1 pack of 20 cigarettes a day for 10 years).
  4. Females who:

    1. Are breastfeeding, or
    2. Have been pregnant within 6 months prior to the study, or
    3. Have a positive pregnancy test at any point during screening or prior to dosing with IMP.
  5. Lifetime history of anaphylaxis and/or a history of severe allergic reaction or significant intolerance to any food or drug in the last 12 months, as assessed by the PI.
  6. Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
  7. . .

    1. Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and, in particular, any of the nasal assessments or viral challenge (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month will be excluded).
    2. Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalized due to epistaxis on any previous occasion.
    3. Any nasal or sinus surgery within 3 months of the first study visit.
  8. . .

    1. Evidence of vaccinations within the 4 weeks prior to the planned date of dosing with IMP.
    2. Intention to receive any vaccination(s) before the last day of follow-up (with the exception of vaccinations recommended for Coronavirus Disease 2019 [COVID-19] as defined by Medicines and Healthcare products Regulatory Agency (MHRA)/government vaccination guidelines).
    3. No travel restrictions apply after the Day 28 [±3 days] follow-up visit; however, we expect participants to be available to attend the clinic at the Day 60, Day 120, and Day 180 follow-up visits.
    4. Receipt of influenza vaccine in the last 6 months prior to the planned date of viral challenge.
  9. Receipt of blood or blood products, or loss (including blood donations) of 550 milliliters (mL) or more of blood during the 3 months prior to the planned dosing with IMP or planned during the 3 months after the final visit.
  10. . .

    1. Receipt of any drug within 3 months prior to the planned date of dosing with IMP.
    2. Receipt of 3 or more investigational drugs within the previous 12 months prior to the planned date of dosing with IMP.
    3. Prior inoculation with a virus from the same virus-family as the challenge virus.
    4. Prior participation in another human viral challenge (HVC) study with a respiratory virus in the preceding 3 months, taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study.
  11. Use or anticipated use during the conduct of the study of concomitant medications (prescription and/or non-prescription), including vitamins or herbal and dietary supplements within the specified windows, unless in the opinion of the study physician/PI, the medication will not interfere with the study procedures or compromise participant safety. Specifically, the following are excluded:

    1. Herbal supplements within 7 days prior to the planned date of dosing with IMP.
    2. Chronically used medications, vitamins, or dietary supplements within 21 days prior to the planned date of dosing with IMP.
    3. Over-the-counter medications (e.g., paracetamol or ibuprofen) where the dose taken over the preceding 7 days prior to the planned date dosing with IMP has exceeded the maximum permissible 24-hour dose (e.g., ≥4 grams paracetamol over the preceding week).
    4. Systemic antiviral administration within 4 weeks of the planned date of dosing with IMP.
  12. . .

    1. Confirmed positive test for drugs of misuse and cotinine on first study visit. One repeat test is allowed at PI discretion.
    2. Recent history or presence of alcohol addiction, or excessive use of alcohol (weekly intake in excess of 28 units alcohol; 1 unit being a half glass of beer, a small glass of wine, or a measure of spirits), or excessive consumption of xanthine-containing substances (e.g., daily intake in excess of 5 cups of caffeinated drinks, e.g., coffee, tea, cola).
  13. A (FEV1) \<80 percent.
  14. Positive (HIV), virus (HBV), or virus (HCV) test (HIV positive - via 3 confirmatory tests - Vidas, Genenius, and Determine; HBV confirmed via hepatitis B surface antigen [HbsAG], hepatitis B surface antibody [anti-HBs], and hepatitis B core antibody [anti-HBc] [immunoglobulin G/immunoglobulin M]; and HCV confirmed via hepatitis C viral load).
  15. Presence of fever, defined as participant presenting with a temperature reading of ≥37.9 degrees Celsius (°C) on Day -7/-6 and/or pre-dose on Day -5.
  16. Those employed or immediate relatives of those employed at hVIVO Services Limited (hVIVO) or the sponsor.
  17. Any other finding that, in the opinion of the PI/investigator, deems the participant unsuitable for the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Arm 1)

    In Cohort 1, up to 30 participants will be randomized to receive a single dose of placebo, administered by subcutaneous (SQ) injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 1, to receive a single dose of placebo by SQ injection prior to viral challenge.

    Drug: Saline placebo

  • Experimental
    CD388 High Dose (Arm 2)

    In Cohort 1, up to 30 participants will be randomized to receive a single dose of 150 milligrams (mg) CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 2, to receive a single dose of 150 mg CD388 by SQ injection prior to viral challenge.

    Combination Product: CD388

  • Experimental
    CD388 Low Dose 1 (Arm 3)

    In Cohort 1, up to 30 participants will be randomized to receive a single dose of 50 mg CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 3, to receive a single dose of 50mg CD388 by SQ injection prior to viral challenge.

    Combination Product: CD388

  • Experimental
    CD388 Low Dose 2 (Optional Arm 4)

    Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 4, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.

    Combination Product: CD388

  • Experimental
    CD388 Low Dose 3 (Optional Arm 5)

    Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 5, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.

    Combination Product: CD388

  • Experimental
    CD388 Low Dose 4 (Optional Arm 6)

    Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 6, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.

    Combination Product: CD388

Interventions

  • DrugSaline placebo

    Sterile normal saline for injection

  • Combination productCD388

    CD388 liquid for injection

06

What researchers measure

Primary outcomes

  1. Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge

    Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (evening [pm]); Days 2, 3, 4, 5, 6, and 7 (morning [am] and pm); Day 8 (am)

  2. Median Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge

    Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (evening [pm]); Days 2, 3, 4, 5, 6, and 7 (morning [am] and pm); Day 8 (am)

Secondary outcomes

  1. Mean Peak Viral Load by qRT-PCR After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  2. Median Peak Viral Load by qRT-PCR After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  3. Time to Confirmed Negative Test by qRT-PCR After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.

    Time frame: From Day 1 (pm) until the first confirmed undetectable assessment after peak measurement, assessed up to Day 8 (am)

  4. Mean Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  5. Median Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  6. Mean Peak Viral Load by Viral Culture After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  7. Median Peak Viral Load by Viral Culture After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  8. Time to Confirmed Negative Test by Viral Culture After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable viral culture measurements in nasal samples starting 1 day post viral challenge.

    Time frame: From Day 1 (pm) until the first confirmed undetectable assessment after peak measurement, assessed up to Day 8 (am)

  9. Mean Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

    Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  10. Median Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

    Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  11. Mean Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

    Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  12. Median Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

    Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  13. Mean Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.

    Time frame: From Day 1 up to Day 8

  14. Median Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.

    Time frame: From Day 1 up to Day 8

  15. Time to Symptom Resolution After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to symptom resolution (i.e., first time with Total Symptom Score \[TSS\] equal to the TSS at baseline after which no further increase above the baseline TSS was observed) as measured by graded daily symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. An individual TSS is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

    Time frame: Starting Day 1, from the time of peak daily symptom score until the time of returning to baseline score, up to Day 8

  16. Number of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  17. Percentage of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  18. Number of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the number of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  19. Percentage of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.

    Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)

  20. Number of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

    Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  21. Percentage of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

    Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  22. Number of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

    Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For symptom scoring measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  23. Percentage of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

    Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For symptom scoring measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  24. Number of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the number of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

    Time frame: • For viral culture measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  25. Percentage of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

    Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

    Time frame: • For viral culture measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)

  26. Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Participants

    Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of participants reporting any solicited AE. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.

    Time frame: From Day -5 (dosing) up to Day 0 (viral challenge)

  27. Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Events

    Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of events reported. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.

    Time frame: From Day -5 (dosing) up to Day 0 (viral challenge)

  28. Occurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Participants

    Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of participants for whom any AE is observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)

    Time frame: From Day -5 (dosing) up to Day 28 (±3 days)

  29. Occurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Events

    Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)

    Time frame: From Day -5 (dosing) up to Day 28 (±3 days)

  30. Occurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Participants

    Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of participants for whom any AE was observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])

    Time frame: From Day -5 (dosing) up to Day 180 (±14 days)

  31. Occurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Events

    Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])

    Time frame: From Day -5 (dosing) up to Day 180 (±14 days)

07

Results

Posted Sep 5, 2024

Participant flow

Up to 168 participants in up to 2 cohorts were planned for enrollment in the study. Due to low participant eligibility, the randomization schedule was changed in Cohort 1 after the first quarantine group to only randomize participants to the 150 mg CD388 and placebo arms. With only 2 participants in the 50 mg CD388 arm, safety and demographic data only have been reported. Based on data from the planned interim analysis of Cohort 1, a decision was made to not proceed with Cohort 2.

Participant flow — Overall Study
MilestonePlacebo50 mg CD388150 mg CD388
Started29228
Completed27228
Not completed200
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up100

Outcome measures

PrimaryMean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge

Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (evening [pm]); Days 2, 3, 4, 5, 6, and 7 (morning [am] and pm); Day 8 (am)
Reported as:
Mean · log[10] copies/milliliter (mL)*hour
Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge
log[10] copies/milliliter (mL)*hourPlacebo150 mg CD388
Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge16.09 ± 11.8610.70 ± 8.01
Statistical analysis
  • Placebo vs 150 mg CD388 · Wilcoxon (Mann-Whitney) · p = 0.0390 (alpha = 0.025 one-sided) · Hodges-lehmann estimator: -1.2 · 95% CI -5.7 to 0.0
PrimaryMedian Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge

Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (evening [pm]); Days 2, 3, 4, 5, 6, and 7 (morning [am] and pm); Day 8 (am)
Reported as:
Median · log[10] copies/mL*hour
Median Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge
log[10] copies/mL*hourPlacebo150 mg CD388
Median Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge8.52 (6.4 to 39.8)6.40 (6.4 to 29.9)
SecondaryMean Peak Viral Load by qRT-PCR After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Mean · log[10] copies/mL
Mean Peak Viral Load by qRT-PCR After Influenza Viral Challenge
log[10] copies/mLPlacebo150 mg CD388
Mean Peak Viral Load by qRT-PCR After Influenza Viral Challenge4.28 ± 2.942.84 ± 2.40
Statistical analysis
  • Placebo vs 150 mg CD388 · Wilcoxon (Mann-Whitney) · p = 0.0185 (alpha = 0.025 one-sided) · Mean difference (net): -1.4 · 95% CI -2.9 to -0.0
SecondaryMedian Peak Viral Load by qRT-PCR After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Median · log[10] copies/mL
Median Peak Viral Load by qRT-PCR After Influenza Viral Challenge
log[10] copies/mLPlacebo150 mg CD388
Median Peak Viral Load by qRT-PCR After Influenza Viral Challenge3.79 (1.0 to 8.5)0.97 (0.9 to 7.5)
SecondaryTime to Confirmed Negative Test by qRT-PCR After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.

Time frame:
From Day 1 (pm) until the first confirmed undetectable assessment after peak measurement, assessed up to Day 8 (am)
Reported as:
Number · hours
Time to Confirmed Negative Test by qRT-PCR After Influenza Viral Challenge
hoursPlacebo150 mg CD388
25th Percentile61.9 (14.7 to 120.3)66.7 (24.3 to 72.4)
Median134.1 (61.9 to NA)79.4 (24.4 to 143.1)
75th Percentile158.3 (134.1 to NA)131.7 (72.4 to NA)
Statistical analysis
  • Placebo vs 150 mg CD388 · Gehan-Wilcoxon · p = 0.0613 (alpha = 0.025 one-sided)
SecondaryMean Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Mean · log[10] copies/mL*hour
Mean Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge
log[10] copies/mL*hourPlacebo150 mg CD388
Mean Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge5.82 ± 3.703.95 ± 1.57
Statistical analysis
  • Placebo vs 150 mg CD388 · Wilcoxon (Mann-Whitney) · p = 0.1587 (alpha = 0.025 one-sided) · Hodges-lehmann estimator: -0.0 · 95% CI -2.4 to 0.0
SecondaryMedian Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Median · log[10] copies/mL*hour
Median Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge
log[10] copies/mL*hourPlacebo150 mg CD388
Median Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge3.29 (3.2 to 14.4)3.29 (3.2 to 9.7)
SecondaryMean Peak Viral Load by Viral Culture After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Mean · log[10] copies/mL
Mean Peak Viral Load by Viral Culture After Influenza Viral Challenge
log[10] copies/mLPlacebo150 mg CD388
Mean Peak Viral Load by Viral Culture After Influenza Viral Challenge2.13 ± 2.101.07 ± 1.18
Statistical analysis
  • Placebo vs 150 mg CD388 · Wilcoxon (Mann-Whitney) · p = 0.0236 (alpha = 0.025 one-sided) · Mean difference (net): -1.1 · 95% CI -2.0 to -0.1
SecondaryMedian Peak Viral Load by Viral Culture After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Median · log[10] copies/mL
Median Peak Viral Load by Viral Culture After Influenza Viral Challenge
log[10] copies/mLPlacebo150 mg CD388
Median Peak Viral Load by Viral Culture After Influenza Viral Challenge0.50 (0.5 to 5.5)0.50 (0.5 to 4.5)
SecondaryTime to Confirmed Negative Test by Viral Culture After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable viral culture measurements in nasal samples starting 1 day post viral challenge.

Time frame:
From Day 1 (pm) until the first confirmed undetectable assessment after peak measurement, assessed up to Day 8 (am)
Reported as:
Number · hours
Time to Confirmed Negative Test by Viral Culture After Influenza Viral Challenge
hoursPlacebo150 mg CD388
25th Percentile71.4 (47.2 to 85.9)62.3 (24.3 to 85.9)
Median85.9 (47.5 to 110.1)78.7 (24.3 to NA)
75th Percentile110.1 (85.9 to NA)86.0 (62.3 to NA)
Statistical analysis
  • Placebo vs 150 mg CD388 · Gehan-Wilcoxon · p = 0.1282 (alpha = 0.025 one-sided)
SecondaryMean Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

Time frame:
Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Mean · TSS points*day
Mean Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge
TSS points*dayPlacebo150 mg CD388
Mean Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge7.66 ± 14.132.22 ± 4.86
Statistical analysis
  • Placebo vs 150 mg CD388 · Wilcoxon (Mann-Whitney) · p = 0.2877 (alpha = 0.025 one-sided) · Mean difference (net): -5.4 · 95% CI -11.2 to 0.3
SecondaryMedian Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

Time frame:
Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Median · TSS points*day
Median Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge
TSS points*dayPlacebo150 mg CD388
Median Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge0.45 (0.0 to 48.3)0.86 (0.0 to 25.2)
SecondaryMean Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

Time frame:
Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Mean · total symptom score
Mean Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge
total symptom scorePlacebo150 mg CD388
Mean Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge3.54 ± 5.341.79 ± 3.12
Statistical analysis
  • Placebo vs 150 mg CD388 · Wilcoxon (Mann-Whitney) · p = 0.2517 (alpha = 0.025 one-sided) · Mean difference (net): -1.8 · 95% CI -4.1 to 0.6
SecondaryMedian Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

Time frame:
Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Median · total symptom score
Median Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge
total symptom scorePlacebo150 mg CD388
Median Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge1.00 (0.0 to 21.0)1.00 (0.0 to 16.0)
SecondaryMean Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.

Time frame:
From Day 1 up to Day 8
Reported as:
Mean · total symptom score
Mean Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge
total symptom scorePlacebo150 mg CD388
Quarantine Day 10.64 ± 1.500.46 ± 0.84
Quarantine Day 22.29 ± 4.600.75 ± 2.12
Quarantine Day 32.79 ± 5.101.25 ± 3.15
Quarantine Day 42.11 ± 3.830.82 ± 1.85
Quarantine Day 51.07 ± 2.120.36 ± 0.87
Quarantine Day 60.79 ± 1.910.39 ± 0.69
Quarantine Day 70.43 ± 1.530.07 ± 0.26
Quarantine Day 8 Discharge0.15 ± 0.600.11 ± 0.42
SecondaryMedian Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.

Time frame:
From Day 1 up to Day 8
Reported as:
Median · total symptom score
Median Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge
total symptom scorePlacebo150 mg CD388
Quarantine Day 10.00 (0.0 to 7.0)0.00 (0.0 to 3.0)
Quarantine Day 20.00 (0.0 to 17.0)0.00 (0.0 to 11.0)
Quarantine Day 30.00 (0.0 to 21.0)0.00 (0.0 to 16.0)
Quarantine Day 40.00 (0.0 to 14.0)0.00 (0.0 to 8.0)
Quarantine Day 50.00 (0.0 to 8.0)0.00 (0.0 to 4.0)
Quarantine Day 60.00 (0.0 to 9.0)0.00 (0.0 to 2.0)
Quarantine Day 70.00 (0.0 to 8.0)0.00 (0.0 to 1.0)
Quarantine Day 8 Discharge0.00 (0.0 to 3.0)0.00 (0.0 to 2.0)
SecondaryTime to Symptom Resolution After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to symptom resolution (i.e., first time with Total Symptom Score \[TSS\] equal to the TSS at baseline after which no further increase above the baseline TSS was observed) as measured by graded daily symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. An individual TSS is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.

Time frame:
Starting Day 1, from the time of peak daily symptom score until the time of returning to baseline score, up to Day 8
Reported as:
Number · hours
Time to Symptom Resolution After Influenza Viral Challenge
hoursPlacebo150 mg CD388
25th Percentile8.4 (6.9 to 31.1)23.3 (6.7 to 54.3)
Median41.5 (8.4 to 72.7)74.8 (23.3 to 96.2)
75th Percentile78.7 (41.5 to NA)133.5 (84.4 to NA)
Statistical analysis
  • Placebo vs 150 mg CD388 · Gehan-Wilcoxon · p = 0.9024 (alpha = 0.025 one-sided)
SecondaryNumber of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Count of participants · Participants
Number of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge
ParticipantsPlacebo150 mg CD388
No qRT-PCR-confirmed Influenza Infection1422
qRT-PCR-confirmed Influenza Infection146
Statistical analysis
  • Placebo vs 150 mg CD388 · Fisher Exact · p = 0.0248 (alpha = 0.025 one-sided)
SecondaryPercentage of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Number · percentage of participants
Percentage of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge
percentage of participantsPlacebo150 mg CD388
No qRT-PCR-confirmed Influenza Infection50.0 (30.6 to 69.4)78.6 (59.0 to 91.7)
qRT-PCR-confirmed Influenza Infection50.0 (30.6 to 69.4)21.4 (8.3 to 41.0)
SecondaryNumber of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the number of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge
ParticipantsPlacebo150 mg CD388
No Positive Quantitative (≥LLOQ) Cell Culture1722
At Least 1 Positive Quantitative (≥LLOQ) Cell Culture116
Statistical analysis
  • Placebo vs 150 mg CD388 · Fisher Exact · p = 0.1224 (alpha = 0.025 one-sided)
SecondaryPercentage of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.

Time frame:
Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge
percentage of participantsPlacebo150 mg CD388
No Positive Quantitative (≥LLOQ) Cell Culture60.7 (40.6 to 78.5)78.6 (59.0 to 91.7)
At Least 1 Positive Quantitative (≥LLOQ) Cell Culture39.3 (21.5 to 59.4)21.4 (8.3 to 41.0)
SecondaryNumber of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

Time frame:
• For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Count of participants · Participants
Number of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
ParticipantsPlacebo150 mg CD388
No qRT-PCR-confirmed Symptomatic Influenza Infection1924
qRT-PCR-confirmed Symptomatic Influenza Infection94
Statistical analysis
  • Placebo vs 150 mg CD388 · Fisher Exact · p = 0.1023 (alpha = 0.025 one-sided)
SecondaryPercentage of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

Time frame:
• For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Number · percentage of participants
Percentage of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
percentage of participantsPlacebo150 mg CD388
No qRT-PCR-confirmed Symptomatic Influenza Infection67.9 (47.6 to 84.1)85.7 (67.3 to 96.0)
qRT-PCR-confirmed Symptomatic Influenza Infection32.1 (15.9 to 52.4)14.3 (4.0 to 32.7)
SecondaryNumber of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

Time frame:
• For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For symptom scoring measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Count of participants · Participants
Number of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge
ParticipantsPlacebo150 mg CD388
No qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection2125
qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection73
Statistical analysis
  • Placebo vs 150 mg CD388 · Fisher Exact · p = 0.1477 (alpha = 0.025 one-sided)
SecondaryPercentage of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

Time frame:
• For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For symptom scoring measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Number · percentage of participants
Percentage of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge
percentage of participantsPlacebo150 mg CD388
No qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection75.0 (55.1 to 89.3)89.3 (71.8 to 97.7)
qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection25.0 (10.7 to 44.9)10.7 (2.3 to 28.2)
SecondaryNumber of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the number of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

Time frame:
• For viral culture measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Count of participants · Participants
Number of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
ParticipantsPlacebo150 mg CD388
No Culture Lab-confirmed Symptomatic Influenza Infection2024
Culture Lab-confirmed Symptomatic Influenza Infection84
Statistical analysis
  • Placebo vs 150 mg CD388 · Fisher Exact · p = 0.1645 (alpha = 0.025 one-sided)
SecondaryPercentage of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge

Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.

Time frame:
• For viral culture measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Reported as:
Number · percentage of participants
Percentage of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
percentage of participantsPlacebo150 mg CD388
No Culture Lab-confirmed Symptomatic Influenza Infection71.4 (51.3 to 86.8)85.7 (67.3 to 96.0)
Culture Lab-confirmed Symptomatic Influenza Infection28.6 (13.2 to 48.7)14.3 (4.0 to 32.7)
SecondaryOccurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Participants

Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of participants reporting any solicited AE. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.

Time frame:
From Day -5 (dosing) up to Day 0 (viral challenge)
Reported as:
Count of participants · Participants
Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Participants
ParticipantsPlacebo50 mg CD388150 mg CD388
Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Participants001
SecondaryOccurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Events

Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of events reported. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.

Time frame:
From Day -5 (dosing) up to Day 0 (viral challenge)
Reported as:
Number · events
Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Events
eventsPlacebo50 mg CD388150 mg CD388
Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Events001
SecondaryOccurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Participants

Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of participants for whom any AE is observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)

Time frame:
From Day -5 (dosing) up to Day 28 (±3 days)
Reported as:
Count of participants · Participants
Occurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Participants
ParticipantsPlacebo50 mg CD388150 mg CD388
Period 1110
Periods 1 and 2412
Period 2312
Periods 2 and 310111
Period 3819
SecondaryOccurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Events

Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)

Time frame:
From Day -5 (dosing) up to Day 28 (±3 days)
Reported as:
Number · events
Occurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Events
eventsPlacebo50 mg CD388150 mg CD388
Period 1110
Periods 1 and 2422
Period 2312
Periods 2 and 312313
Period 39211
SecondaryOccurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Participants

Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of participants for whom any AE was observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])

Time frame:
From Day -5 (dosing) up to Day 180 (±14 days)
Reported as:
Count of participants · Participants
Occurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Participants
ParticipantsPlacebo50 mg CD388150 mg CD388
Period 3819
Periods 3 and 416119
Period 49014
Across All Periods19121
SecondaryOccurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Events

Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])

Time frame:
From Day -5 (dosing) up to Day 180 (±14 days)
Reported as:
Number · events
Occurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Events
eventsPlacebo50 mg CD388150 mg CD388
Period 39211
Periods 3 and 421232
Period 412021
Across All Periods25434

Adverse events

Collected over Adverse events (AEs) were collected for all participants from the time of signing the study-specific informed consent form until the last scheduled follow-up visit (Day 180 ±14 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/29 (0%)0/29 (0%)19/29 (65.5%)
50 mg CD3880/2 (0%)0/2 (0%)1/2 (50%)
150 mg CD3880/28 (0%)0/28 (0%)21/28 (75%)
All Arms0/59 (0%)0/59 (0%)41/59 (69.5%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlacebo50 mg CD388150 mg CD388All Arms
Upper respiratory tract infectionInfections and infestations12/291/215/2828/59
ArthralgiaMusculoskeletal and connective tissue disorders0/291/20/281/59
Pain in extremityMusculoskeletal and connective tissue disorders0/291/20/281/59
DyspnoeaRespiratory, thoracic and mediastinal disorders0/291/20/281/59
HeadacheNervous system disorders2/290/24/286/59
Aspartate aminotransferase increasedInvestigations1/290/23/284/59
Injection site painGeneral disorders0/290/21/281/59
Oral herpesInfections and infestations1/290/21/282/59
Bacterial vaginosisInfections and infestations0/290/21/281/59
TonsillitisInfections and infestations0/290/21/281/59

Baseline characteristics

The Safety Population included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they received.

Age, Continuous
Age, Continuous(years)Placebo50 mg CD388150 mg CD388Total
Mean33.03 ± 8.2127.50 ± 2.1233.82 ± 7.8633.22 ± 7.92
Age, Continuous
Age, Continuous(years)Placebo50 mg CD388150 mg CD388Total
Median31.00 (22.0 to 51.0)27.50 (26.0 to 29.0)32.00 (21.0 to 51.0)31.00 (21.0 to 51.0)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo50 mg CD388150 mg CD388Total
Female901322
Male2021537
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo50 mg CD388150 mg CD388Total
Hispanic or Latino0000
Not Hispanic or Latino2922859
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo50 mg CD388150 mg CD388Total
American Indian or Alaska Native0000
Asian2125
Native Hawaiian or Other Pacific Islander0000
Black or African American1034
White2412348
More than one race0000
Unknown or Not Reported2002
Region of Enrollment
Region of Enrollment(participants)Placebo50 mg CD388150 mg CD388Total
United Kingdom2922859
Weight
Weight(kilograms (kg))Placebo50 mg CD388150 mg CD388Total
Mean76.29 ± 13.2672.40 ± 2.5579.68 ± 19.0277.77 ± 16.04
Weight
Weight(kg)Placebo50 mg CD388150 mg CD388Total
Median72.90 (54.2 to 100.8)72.40 (70.6 to 74.2)75.60 (54.2 to 112.0)75.20 (54.2 to 112.0)

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • hVIVO Services Limited
    London, E1 2AX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2023, 10 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 10 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2022
First posted
Aug 31, 2022
StartActual
Sep 9, 2022
Primary completionActual
Jul 17, 2023
CompletionActual
Jul 17, 2023
Results first posted
Sep 5, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05523089
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Sep 9, 2022
Primary completion
Jul 17, 2023
Completion
Jul 17, 2023
Results posted
Sep 5, 2024
Last update
Sep 19, 2024

Study contacts

Ozlem Equils, MD
study director · Cidara Therapeutics Inc.
Arun Anandakumar, MD
principal investigator · hVIVO Services Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-1406

Start the discussion